DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Naritomi, Y.
Right arrow Articles by Sugiyama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naritomi, Y.
Right arrow Articles by Sugiyama, Y.

Vol. 31, Issue 5, 580-588, May 2003

Utility of Hepatocytes in Predicting Drug Metabolism: Comparison of Hepatic Intrinsic Clearance in Rats and Humans in Vivo and in Vitro

Yoichi Naritomi, Shigeyuki Terashita, Akira Kagayama, and Yuichi Sugiyama

Biopharmaceutical and Pharmacokinetic Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (Y.N., S.T., A.K.); and Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (Y.S.)

We investigated hepatic in vitro intrinsic clearance (CLint,in vitro) in freshly isolated or cryopreserved hepatocytes and compared with CLint,in vivo by using nine model compounds, FK1052, FK480, diazepam, diltiazem, troglitazone, quinotolast, FK079, zidovudine, and acetaminophen, in rats and humans. The compounds showed a broad range of in vivo hepatic extraction ratios (rat, 0.05-0.93; humans, 0.03-0.76) and were metabolized by hepatic P450, UDP-glucuronosyltransferase, sulfotransferase, and/or esterase. CLint,in vitro was determined from substrate disappearance rate at 1 µM in hepatocytes. CLint,in vivo was calculated from in vivo pharmacokinetic data using two frequently used mathematical models (the well stirred and dispersion models). When estimating rat CLint,in vitro in freshly isolated hepatocytes, the rat scaling factor values (CLint,in vivo/CLint,in vitro) showed marked difference among the model compounds (0.2-73.1-fold). The rat CLint,in vitro values in freshly isolated hepatocytes were in good agreement with these in cryopreserved hepatocytes. Human CLint,in vitro were determined by use of cryopreserved hepatocytes. When human CLint,in vitro was regarded as the predicted CLint,in vivo, the observed and predicted CLint,in vivo for FK1052, FK480, troglitazone, and FK079 differed markedly (12.4-199.0-fold). In contrast, using human CLint,in vitro corrected with the rat scaling factors yielded better predictions of CLint,in vivo that were mostly within 5-fold of the actual values. These results make the evaluation using hepatocytes more useful and provide a basis for predicting hepatic clearance using hepatocytes.


Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.